Your browser doesn't support javascript.
loading
Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).
Fuchs, M A; Yuan, C; Sato, K; Niedzwiecki, D; Ye, X; Saltz, L B; Mayer, R J; Mowat, R B; Whittom, R; Hantel, A; Benson, A; Atienza, D; Messino, M; Kindler, H; Venook, A; Innocenti, F; Warren, R S; Bertagnolli, M M; Ogino, S; Giovannucci, E L; Horvath, E; Meyerhardt, J A; Ng, K.
Afiliación
  • Fuchs MA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston.
  • Yuan C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston.
  • Sato K; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston.
  • Niedzwiecki D; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston.
  • Ye X; Alliance Statistics and Data Center, Duke University Medical Center, Durham.
  • Saltz LB; Alliance Statistics and Data Center, Duke University Medical Center, Durham.
  • Mayer RJ; Memorial Sloan-Kettering Cancer Center, New York.
  • Mowat RB; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston.
  • Whittom R; Toledo Community Hospital Oncology Program, Toledo, USA.
  • Hantel A; Hôpital du Sacré-Coeur de Montréal, Montreal, Canada.
  • Benson A; Edward Cancer Center, Naperville.
  • Atienza D; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago.
  • Messino M; Virginia Oncology Associates, Norfolk.
  • Kindler H; Southeast Cancer Control Consortium, Mission Hospitals-Memorial Campus, Asheville.
  • Venook A; University of Chicago, Chicago.
  • Innocenti F; University of California at San Francisco Comprehensive Cancer Center, San Francisco.
  • Warren RS; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill.
  • Bertagnolli MM; University of California at San Francisco Comprehensive Cancer Center, San Francisco.
  • Ogino S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston.
  • Giovannucci EL; Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston.
  • Horvath E; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston.
  • Meyerhardt JA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston.
  • Ng K; Division of MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston.
Ann Oncol ; 28(6): 1359-1367, 2017 Jun 01.
Article en En | MEDLINE | ID: mdl-28327908
BACKGROUND: Observational studies suggest that higher levels of 25-hydroxyvitamin D3 (25(OH)D) are associated with a reduced risk of colorectal cancer and improved survival of colorectal cancer patients. However, the influence of vitamin D status on cancer recurrence and survival of patients with stage III colon cancer is unknown. PATIENTS AND METHODS: We prospectively examined the influence of post-diagnosis predicted plasma 25(OH)D on outcome among 1016 patients with stage III colon cancer who were enrolled in a National Cancer Institute-sponsored adjuvant therapy trial (CALGB 89803). Predicted 25(OH)D scores were computed using validated regression models. We examined the influence of predicted 25(OH)D scores on cancer recurrence and mortality (disease-free survival; DFS) using Cox proportional hazards. RESULTS: Patients in the highest quintile of predicted 25(OH)D score had an adjusted hazard ratio (HR) for colon cancer recurrence or mortality (DFS) of 0.62 (95% confidence interval [CI], 0.44-0.86), compared with those in the lowest quintile (Ptrend = 0.005). Higher predicted 25(OH)D score was also associated with a significant improvement in recurrence-free survival and overall survival (Ptrend = 0.01 and 0.0004, respectively). The benefit associated with higher predicted 25(OH)D score appeared consistent across predictors of cancer outcome and strata of molecular tumor characteristics, including microsatellite instability and KRAS, BRAF, PIK3CA, and TP53 mutation status. CONCLUSION: Higher predicted 25(OH)D levels after a diagnosis of stage III colon cancer may be associated with decreased recurrence and improved survival. Clinical trials assessing the benefit of vitamin D supplementation in the adjuvant setting are warranted. CLINICALTRIALS.GOV IDENTIFIER: NCT00003835.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vitamina D / Neoplasias del Colon / Recurrencia Local de Neoplasia Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vitamina D / Neoplasias del Colon / Recurrencia Local de Neoplasia Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido